A recent report by the Government Accountability Office found that despite the substantial rebates private plans received for Medicare Part D medications from drug manufacturers, these rebates did not lower consumer costs. The GAO also found that payments by beneficiaries were often more than the plan sponsor’s payment after accounting for rebates. Read the report here.
Last Updated on September 21, 2023 by Aimed Alliance
